首页|The development of neutralizing antibodies against SARS-CoV-2 and their common features
The development of neutralizing antibodies against SARS-CoV-2 and their common features
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.
COVID-19SARS-CoV-2neutralizing antibodyepitopeRBD
Liu Daisy Liu、Chaoyang Lian、Leng-Siew Yeap、Fei-Long Meng
展开 >
State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology
University of Chinese Academy of Sciences, Shanghai 200031, China
NSTL
